Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosis
OBJECTIVE:To determine the effect of dalfampridine (4-aminopyridine), a broad-spectrum, voltage-dependent potassium channel blocker, on patients with trigeminal nerve dysfunction due to multiple sclerosis (MS). METHODS:We reviewed histories of 71 patients in our clinic with clinically definite MS wh...
Gespeichert in:
| Veröffentlicht in: | Neurology 2014-10, Vol.83 (18), p.1610-1612 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1612 |
|---|---|
| container_issue | 18 |
| container_start_page | 1610 |
| container_title | Neurology |
| container_volume | 83 |
| creator | Birnbaum, Gary Iverson, Jane |
| description | OBJECTIVE:To determine the effect of dalfampridine (4-aminopyridine), a broad-spectrum, voltage-dependent potassium channel blocker, on patients with trigeminal nerve dysfunction due to multiple sclerosis (MS).
METHODS:We reviewed histories of 71 patients in our clinic with clinically definite MS who were treated with dalfampridine for at least 2 to 3 months. Of the 71 patients, 5 had a history of either trigeminal neuralgia or altered facial sensation.
RESULTS:Of these 5 patients, 3 with preexisting trigeminal neuralgia had a marked worsening of facial pain in close proximity to starting dalfampridine. One patient with altered facial sensation developed trigeminal pain after being on dalfampridine for 18 months. Pain in this individual rapidly subsided when dalfampridine was discontinued. Pain in the worsened 3 patients persisted, became more refractory to previously effective medications, and in one instance required trigeminal surgery for pain control.
CONCLUSIONS:Dalfampridine should be used with caution in persons with trigeminal neuralgia due to MS.
CLASSIFICATION OF EVIDENCE:This study provides Class IV evidence that treatment with dalfampridine may precipitate or exacerbate preexisting trigeminal neuralgia. |
| doi_str_mv | 10.1212/WNL.0000000000000931 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1647014778</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1618140863</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4441-88d645b8e73e91346f43088c4f9bce3b991dc10873467559c30d4d9d739996453</originalsourceid><addsrcrecordid>eNqNkUtPxCAUhYnR6Pj4B8awMXFThUILLI3vZKIbjcZNw9BbB6WdEaiT-fdiZnzEhZEFLM53uHAOQruUHNKc5kf318ND8nMpRlfQgBZ5mZUsf1hFA0JymTEp5AbaDOGZkCQKtY428gTRghQD9HiqXaPbqbe17QC3eo61ifZNR8AubV3E0dsnaG2nHe6g99o9WY1th6c62qQHPLNxjNveRTt1gINx4CfBhm201mgXYGd5bqG787Pbk8tseHNxdXI8zAznnGZS1iUvRhIEA0UZLxvOiJSGN2pkgI2UorWhRIokiaJQhpGa16oWTCmVnGwLHSzunfrJaw8hVq0NBpzTHUz6UNGSC0K5EPIfKJWUE1myhPIFatJngoemShm12s8rSqqPAqpUQPW7gGTbW07oRy3UX6bPxBOwvwR0MCl7rztjwzcnFc2J-ODkgptNXAQfXlw_A1-NQbs4_vsN75X8nh4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1618140863</pqid></control><display><type>article</type><title>Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosis</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>Alma/SFX Local Collection</source><creator>Birnbaum, Gary ; Iverson, Jane</creator><creatorcontrib>Birnbaum, Gary ; Iverson, Jane</creatorcontrib><description>OBJECTIVE:To determine the effect of dalfampridine (4-aminopyridine), a broad-spectrum, voltage-dependent potassium channel blocker, on patients with trigeminal nerve dysfunction due to multiple sclerosis (MS).
METHODS:We reviewed histories of 71 patients in our clinic with clinically definite MS who were treated with dalfampridine for at least 2 to 3 months. Of the 71 patients, 5 had a history of either trigeminal neuralgia or altered facial sensation.
RESULTS:Of these 5 patients, 3 with preexisting trigeminal neuralgia had a marked worsening of facial pain in close proximity to starting dalfampridine. One patient with altered facial sensation developed trigeminal pain after being on dalfampridine for 18 months. Pain in this individual rapidly subsided when dalfampridine was discontinued. Pain in the worsened 3 patients persisted, became more refractory to previously effective medications, and in one instance required trigeminal surgery for pain control.
CONCLUSIONS:Dalfampridine should be used with caution in persons with trigeminal neuralgia due to MS.
CLASSIFICATION OF EVIDENCE:This study provides Class IV evidence that treatment with dalfampridine may precipitate or exacerbate preexisting trigeminal neuralgia.</description><identifier>ISSN: 0028-3878</identifier><identifier>EISSN: 1526-632X</identifier><identifier>DOI: 10.1212/WNL.0000000000000931</identifier><identifier>PMID: 25261505</identifier><identifier>CODEN: NEURAI</identifier><language>eng</language><publisher>Hagerstown, MD: American Academy of Neurology</publisher><subject>4-Aminopyridine - administration & dosage ; 4-Aminopyridine - adverse effects ; Biological and medical sciences ; Female ; Humans ; Immunomodulators ; Male ; Medical sciences ; Middle Aged ; Multiple Sclerosis - complications ; Multiple Sclerosis - drug therapy ; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis ; Neurology ; Pharmacology. Drug treatments ; Potassium Channel Blockers ; Trigeminal Neuralgia - chemically induced ; Trigeminal Neuralgia - etiology</subject><ispartof>Neurology, 2014-10, Vol.83 (18), p.1610-1612</ispartof><rights>2014 American Academy of Neurology</rights><rights>2015 INIST-CNRS</rights><rights>2014 American Academy of Neurology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4441-88d645b8e73e91346f43088c4f9bce3b991dc10873467559c30d4d9d739996453</citedby><cites>FETCH-LOGICAL-c4441-88d645b8e73e91346f43088c4f9bce3b991dc10873467559c30d4d9d739996453</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28912075$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25261505$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Birnbaum, Gary</creatorcontrib><creatorcontrib>Iverson, Jane</creatorcontrib><title>Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosis</title><title>Neurology</title><addtitle>Neurology</addtitle><description>OBJECTIVE:To determine the effect of dalfampridine (4-aminopyridine), a broad-spectrum, voltage-dependent potassium channel blocker, on patients with trigeminal nerve dysfunction due to multiple sclerosis (MS).
METHODS:We reviewed histories of 71 patients in our clinic with clinically definite MS who were treated with dalfampridine for at least 2 to 3 months. Of the 71 patients, 5 had a history of either trigeminal neuralgia or altered facial sensation.
RESULTS:Of these 5 patients, 3 with preexisting trigeminal neuralgia had a marked worsening of facial pain in close proximity to starting dalfampridine. One patient with altered facial sensation developed trigeminal pain after being on dalfampridine for 18 months. Pain in this individual rapidly subsided when dalfampridine was discontinued. Pain in the worsened 3 patients persisted, became more refractory to previously effective medications, and in one instance required trigeminal surgery for pain control.
CONCLUSIONS:Dalfampridine should be used with caution in persons with trigeminal neuralgia due to MS.
CLASSIFICATION OF EVIDENCE:This study provides Class IV evidence that treatment with dalfampridine may precipitate or exacerbate preexisting trigeminal neuralgia.</description><subject>4-Aminopyridine - administration & dosage</subject><subject>4-Aminopyridine - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple Sclerosis - complications</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</subject><subject>Neurology</subject><subject>Pharmacology. Drug treatments</subject><subject>Potassium Channel Blockers</subject><subject>Trigeminal Neuralgia - chemically induced</subject><subject>Trigeminal Neuralgia - etiology</subject><issn>0028-3878</issn><issn>1526-632X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtPxCAUhYnR6Pj4B8awMXFThUILLI3vZKIbjcZNw9BbB6WdEaiT-fdiZnzEhZEFLM53uHAOQruUHNKc5kf318ND8nMpRlfQgBZ5mZUsf1hFA0JymTEp5AbaDOGZkCQKtY428gTRghQD9HiqXaPbqbe17QC3eo61ifZNR8AubV3E0dsnaG2nHe6g99o9WY1th6c62qQHPLNxjNveRTt1gINx4CfBhm201mgXYGd5bqG787Pbk8tseHNxdXI8zAznnGZS1iUvRhIEA0UZLxvOiJSGN2pkgI2UorWhRIokiaJQhpGa16oWTCmVnGwLHSzunfrJaw8hVq0NBpzTHUz6UNGSC0K5EPIfKJWUE1myhPIFatJngoemShm12s8rSqqPAqpUQPW7gGTbW07oRy3UX6bPxBOwvwR0MCl7rztjwzcnFc2J-ODkgptNXAQfXlw_A1-NQbs4_vsN75X8nh4</recordid><startdate>20141028</startdate><enddate>20141028</enddate><creator>Birnbaum, Gary</creator><creator>Iverson, Jane</creator><general>American Academy of Neurology</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>20141028</creationdate><title>Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosis</title><author>Birnbaum, Gary ; Iverson, Jane</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4441-88d645b8e73e91346f43088c4f9bce3b991dc10873467559c30d4d9d739996453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>4-Aminopyridine - administration & dosage</topic><topic>4-Aminopyridine - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple Sclerosis - complications</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</topic><topic>Neurology</topic><topic>Pharmacology. Drug treatments</topic><topic>Potassium Channel Blockers</topic><topic>Trigeminal Neuralgia - chemically induced</topic><topic>Trigeminal Neuralgia - etiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Birnbaum, Gary</creatorcontrib><creatorcontrib>Iverson, Jane</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>Neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Birnbaum, Gary</au><au>Iverson, Jane</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosis</atitle><jtitle>Neurology</jtitle><addtitle>Neurology</addtitle><date>2014-10-28</date><risdate>2014</risdate><volume>83</volume><issue>18</issue><spage>1610</spage><epage>1612</epage><pages>1610-1612</pages><issn>0028-3878</issn><eissn>1526-632X</eissn><coden>NEURAI</coden><abstract>OBJECTIVE:To determine the effect of dalfampridine (4-aminopyridine), a broad-spectrum, voltage-dependent potassium channel blocker, on patients with trigeminal nerve dysfunction due to multiple sclerosis (MS).
METHODS:We reviewed histories of 71 patients in our clinic with clinically definite MS who were treated with dalfampridine for at least 2 to 3 months. Of the 71 patients, 5 had a history of either trigeminal neuralgia or altered facial sensation.
RESULTS:Of these 5 patients, 3 with preexisting trigeminal neuralgia had a marked worsening of facial pain in close proximity to starting dalfampridine. One patient with altered facial sensation developed trigeminal pain after being on dalfampridine for 18 months. Pain in this individual rapidly subsided when dalfampridine was discontinued. Pain in the worsened 3 patients persisted, became more refractory to previously effective medications, and in one instance required trigeminal surgery for pain control.
CONCLUSIONS:Dalfampridine should be used with caution in persons with trigeminal neuralgia due to MS.
CLASSIFICATION OF EVIDENCE:This study provides Class IV evidence that treatment with dalfampridine may precipitate or exacerbate preexisting trigeminal neuralgia.</abstract><cop>Hagerstown, MD</cop><pub>American Academy of Neurology</pub><pmid>25261505</pmid><doi>10.1212/WNL.0000000000000931</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-3878 |
| ispartof | Neurology, 2014-10, Vol.83 (18), p.1610-1612 |
| issn | 0028-3878 1526-632X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1647014778 |
| source | MEDLINE; Journals@Ovid Complete; Alma/SFX Local Collection |
| subjects | 4-Aminopyridine - administration & dosage 4-Aminopyridine - adverse effects Biological and medical sciences Female Humans Immunomodulators Male Medical sciences Middle Aged Multiple Sclerosis - complications Multiple Sclerosis - drug therapy Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Neurology Pharmacology. Drug treatments Potassium Channel Blockers Trigeminal Neuralgia - chemically induced Trigeminal Neuralgia - etiology |
| title | Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T08%3A57%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dalfampridine%20may%20activate%20latent%20trigeminal%20neuralgia%20in%20patients%20with%20multiple%20sclerosis&rft.jtitle=Neurology&rft.au=Birnbaum,%20Gary&rft.date=2014-10-28&rft.volume=83&rft.issue=18&rft.spage=1610&rft.epage=1612&rft.pages=1610-1612&rft.issn=0028-3878&rft.eissn=1526-632X&rft.coden=NEURAI&rft_id=info:doi/10.1212/WNL.0000000000000931&rft_dat=%3Cproquest_cross%3E1618140863%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1618140863&rft_id=info:pmid/25261505&rfr_iscdi=true |